Glenmark Pharmaceuticals

Buy Glenmark Pharma For Short Term

Buy IDBI Bank With Stop Loss Of Rs 127Stock market analyst Somil Mehta of Sharekhan has maintained 'buy' rating on Glenmark Pharma Ltd stock to achieve a target of Rs 330.

The strict stop loss for the stock is Rs 265.

Today, the stock of the company opened at Rs 284.30 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 303.80 and a low of Rs 216.90 on BSE.

Current EPS & P/E ratio stood at 16.05 and 17.73 respectively.

Buy Glenmark For Short Term

Buy Glenmark For Short TermStock market analyst Hitesh Chotalia has maintained 'buy' rating on Glenmark Pharmaceutical Ltd stock to achieve short term target of Rs 315.

According to analyst, the interested investors can buy the stock with strict stop loss of Rs 280.

The stock of the company, on Sep 01, closed at Rs 288.65 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 303.80 and a low of Rs 214.60 on BSE.

Current EPS & P/E ratio stood at 16.05 and 18.09 respectively.

Glenmark Q1 net profit jumps nearly three-fold to Rs 155 crore

Glenmark Q1 net profit jumps nearly three-fold to Rs 155 croreGlenmark Pharmaceuticals has declared its April-June quarter financial results for the fiscal year 2010-11. The pharma company has announced that it has registered an impressive three fold net profit rise in the quarter under review.

Glenmark gets approval from USFDA for asthma drug

GlenmarkPharmaceutical Company, Glenmark said on Wednesday that it has got approval from the US regulator, USFDA for introducing its treatment for asthma.

Its generic theophylline tablets are for treating lung-related diseases. It will be selling these medicines in the American markets.

The approval was given to Glenmark Generics Inc (GGI), which is a subsidiary of Glenmark Generics Ltd. It can now start marketing and distributing this drug, that will be available in 400 mg and 600mg dosages.

Short Term Buy Call For Glenmark

Short Term Buy Call For GlenmarkStock market analyst Hitesh Chotalia has maintained 'buy' rating on Glenmark Pharmaceutical Ltd stock to achieve a short term target of Rs 315.

According to analyst, the investors can buy the stock with stop loss of Rs 270,

The stock of the company, on July 08, closed at Rs 279.90 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 303.80 and a low of Rs 210.50 on BSE.

Current EPS & P/E ratio stood at 12.27 and 23.12 respectively.

Short Term Buy Call For Glenmark Pharma

Short Term Buy Call For Glenmark Pharma        Stock market analyst Hitesh Chotalia has maintained 'buy' rating on Glenmark Pharmaceutical Ltd stock with short term target of Rs 300.

According to analyst, the investors can hold the stock with stop loss of Rs 264.

Today, the stock of the company opened at Rs 275.50 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 303.80 and a low of Rs 210.50 on BSE.

Current EPS & P/E ratio stood at 12.27 and 22.68 respectively.

Glenmark Pharma Intraday Buy Call

Glenmark Pharma Intraday Buy CallTechnical Analyst Anil Singhvi has maintained 'buy' rating on Glenmark Pharmaceutical Ltd stock to achieve an intraday target of Rs 296.

According to him, interested traders can purchase the stock with a stop loss of Rs 276.

The shares of the company, on May 06, closed at Rs 281.95 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 303.80 and a low of Rs 165.65 on BSE.

Current EPS & P/E ratio stood at 8.33 and 33.66 respectively.

Glenmark makes a hatrick

GlenmarkBy signing the third licensing pact with a period of just seven days, pharmaceutical company, Glenmark Glenmark Pharmaceuticals Ltd., has made a hatrick.

This third deal has been signed between Glenmark and US unit of Taro Pharmaceutical Industries. It is going to deal in the branded product category.

A statement said that Glenmark's generic unit, Glenmark Generic will be making a US FDA approved drug for Taro. It will in return get milestone payments and also royalty on sales.

Glenmark Generics ties up with Par Pharmaceuticals to market ezetimibe

Glenmark Generics ties up with Par Pharmaceuticals to market ezetimibeSubsidiary of Glenmark Pharmaceuticals, Glenmark Generics Ltd. announced on Tuesday that the company has entered in to an agreement with the US-based Par Pharmaceuticals to market ezetimibe, the generic version of Zetia tablets produced by Merck-Schering Plough.

As per the agreement the companies would share the profit generated from sale of the ezetimibe tablets, which targets at a market worth $1.4 billion enjoyed by cholesterol modifying agent Zetia tablets in the US.

Glenmark licenses out painkiller to Sanofi-Aventis

Glenmark licenses out painkiller to Sanofi-AventisIndian pharmaceutical company, Glenmark Pharmaceuticals Ltd. announced that it has licensed out the rights to develop and commercial its painkiller to Sanofi-Aventis S. A. Sanofi is a French company and had been waiting for long to get the rights.

Post the declaration, the shares of Glenmark reached its 52-week high. This happened since the agreement is looked as a new lease of life for the research and development facility of Glenmark.

The company was hit hard when the old license deals expired and there was nothing visible in the near future till now.

Glenmark Generics Gets USFDA Nod For Norethindrone Tabs

Glenmark Generics Gets USFDA Nod For Norethindrone TabsGlenmark Generics, USA, a division of Glenmark Generics, has got US FDA nod for Norethindrone tabs, their generic version of Nor- QD.

Norethindrone tablets will be sold under the trade name Heather and distribution is expected to commence shortly.

Presently, Glenmark is the single Indian company to be given an ANDA sanction on an oral contraceptive pill. The US contraceptive business has historically been the biggest of the seven top markets with sales hitting $4.5 billion during the 12 month period ending December 2009.

Glenmark settles row with Glaxo as its gets IPO nod from SEBI

Glenmark settles row with Glaxo as its gets IPO nod from SEBIThe row between Glenmark Pharmaceuticals Ltd. and GlaxoSmithKline (GSK) has come to a resolve, a statement said on Monday. The conflict which was covering patent actions regarding the usage of GSK's Malarone, malaria treatment tablets, finally came to an end with the settlement of the litigations.

Malarone is a generic version from GSK and it had filed a suit against Glenmark.

Glenmark reaches dead-end with GSK on patent dispute

Glenmark-GSKThe two global pharmaceutical majors Glenmark Pharmaceuticals and GlaxoSmithKline LLC have recently announced that the duo have settled its patent issues over the doses of atovaquone and proguanil hydrochloride drug, the generic version of GSK's Malarone malaria treatment tablets.

In fact, according to the terms and conditions of the deal, Glenmark Generics will be able to market and distribute the generic version of Malarone tablets across various markets.

Glenmark Pharmaceuticals Ltd Term Buy Call: StocksIdea.com

Glenmark-PharmaGlenmark Pharmaceuticals Limited was incorporated in the year 1977. Glenmark is an India-based one of the fastest growing pharmaceutical company headquartered at Mumbai. Glenmark has built a visible and growing branded generic formulation presence across all its markets in Asia, Africa and CIS countries. A number of its products have emerged as brand leaders in India and these markets.

Buy Glenmark Pharma With Stoploss Of Rs 249

Buy Glenmark Pharma With Stoploss Of Rs 249Stock market analysts are of the view that investors can buy Glenmark Pharmaceutical Ltd stock to achieve an intraday target between Rs 258-261.

According to them, investors can buy the stock with a strict stop loss of Rs 249.

Shares of the company, on Friday (Nov 20), closed at Rs 254.10 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 346 and a low of Rs 119.15 on BSE.

Current EPS & P/E ratio of the stock stood at 7.86 & 32.50.

Glenmark Pharmaceuticals to raise Rs 300 – 350 crore

Glenmark Pharmaceuticals to raise Rs 300 – 350 croreIndia's leading drugmaker Glenmark Pharmaceuticals has revealed the company plans to raise around Rs 300 -350 crore through issue of shares to qualified institutional buyers on a private placement basis.

The committee of directors has decided to allot equity shares to qualified institutional buyers.

The Glenmark QIP opened on Thursday and will close before the market opens on Friday.

Buy Glenmark To Achieve Target Of Rs 300: Hitendra Vasudeo

Buy Glenmark To Achieve Target Of Rs 300: Hitendra VasudeoStock market analyst Hitendra Vasudeo of stockmechanics.com maintained ‘Buy’ rating on Glenmark Pharmaceuticals to achieve a target between Rs 274 – Rs 300 in 2-3 trading sessions.

According to Mr. Vasudeo, interested investors can buy the stock around Rs 257.80-Rs 248 with a strict stop loss of Rs 241.

Glenmark arm launches Fosinopril Sodium and Hydrochlorothiazide tablets in US

Glenmark arm launches Fosinopril Sodium and Hydrochlorothiazide tablets in USGlenmark Generics Inc., USA (GGI), the US subsidiary of Glenmark Pharmaceuticals, has finally initiated the launch of Fosinopril Sodium and Hydrochlorothiazide tablets in the U.S. market.

The company stated in a communiqué that Fosinopril Sodium and Hydrochlorothiazide (HCTZ) tablets are available in both 10mg/12.5mg and 20mg strengths and are indicated for the treatment of hypertension.

Glenmark Pharmaceuticals posts disappointing results; Q4 net dips 55%

Glenmark Pharmaceuticals posts disappointing results; Q4 net dips 55% Pharmaceutical major Glenmark Pharmaceuticals has registered a decline of 55 per cent in its net profit, which dropped to Rs 57.28 crore for the quarter ended March 31,
2009, compared to Rs 130.14 crore for the quarter ended March 31, 2008.

In addition, the pharmaceutical firm has also witnessed a downfall of 38 per cent in its total income, which slipped to Rs 255.07 crore for the quarter ended March 31, 2009, as compared to Rs 411.90 crore for the quarter ended March 31, 2008.

Glenmark gets USFDA nod for Alclometasone Dipropinate Cream

Glenmark gets USFDA nod for Alclometasone Dipropinate CreamGlenmark Generics Limited (GGL), a subsidiary of Glenmark Pharmaceuticals Limited, has received ANDA approval from the United States Food and Drug Administration
(USFDA) for Alclometasone Dipropionate Cream, 0.05%. The company will commence marketing and distribution of this product in the US market immediately.

Alcometasone Dipropionate is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.




Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate


Syndicate content